Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and Non-stimulants (Atomoxetine, Bupropion, Guanfacine, an

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, by Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate) and Non-stimulants (Atomoxetine, Bupropion, Guanfacine, and Clonidine), by Age Group (Pediatric and Adolescent, and Adult), by Distribution Channel (Specialty Clinics, Hospital Pharmacies, Retail Pharmacies, and E-commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

The global attention deficit hyperactivity disorder (ADHD) therapeutics market comprises therapeutics used for the treatment of attention deficit hyperactivity disorder. There are various therapeutics such as stimulants, which include stimulant drugs such as Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, and Lisdexamfetamine Dimesylate and non-stimulant drugs such as Atomoxetine, Bupropion, Guanfacine, and Clonidine. There are three types of attention deficit hyperactivity disorder (ADHD) such as Predominantly Inattentive Presentation, Predominantly Hyperactive-Impulsive Presentation, and Combined Presentation and various causes of attention deficit hyperactivity disorder (ADHD) include brain injury, alcohol and tobacco use during pregnancy, premature delivery, and low birth weight.
Market Dynamics
Key players are focusing on technological advancements to strengthen their position in the global attention deficit hyperactivity disorder (ADHD) therapeutics market. For instance, in June 2020, Akili Interactive Labs, a digital medicine prescription company in the U.S., received the U.S. Food Drug and Administration clearance for EndeavorRxTM (AKL-T01), a prescription medicine treatment for children with attention deficit hyperactivity disorder (ADHD). EndeavorRxTM is a captivating video game experience to improve attention in children suffering from ADHD.
Key features of the study:
This report studies the current scenario as well as the future potential of the global attention deficit hyperactivity disorder therapeutics market. The market for attention deficit hyperactivity disorder therapeutics is segmented on basis of drug type, age group, distribution channel, and region.
This report provides in-depth analysis of the global attention deficit hyperactivity disorder therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2022 - 2028), considering 2021 as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by leading players.
It profiles leading players in the global attention deficit hyperactivity disorder therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
The global attention deficit hyperactivity disorder therapeutics market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global attention deficit hyperactivity disorder therapeutics market
Detailed Segmentation:
Global Attention Deficit Hyperactivity Disorder Therapeutics Market, By Drug Type:
Stimulants
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-stimulants
Atomoxetine
Bupropion
Guanfacine
Clonidine
Global Attention Deficit Hyperactivity Disorder Therapeutics Market, By Age Group:
Pediatric and Adolescent
Adult
Global Attention Deficit Hyperactivity Disorder Therapeutics Market, By Distribution Channel :
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-commerce
Global Attention Deficit Hyperactivity Disorder Therapeutics Market, By Region:
North America
By Drug Type:
Stimulants
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-stimulants
Atomoxetine
Bupropion
Guanfacine
Clonidine
By Age Group :
Pediatric and Adolescent
Adult
By Distribution Channel :
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-commerce
By Country:
U.S.
Canada
Latin America
By Drug Type:
Stimulants
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-stimulants
Atomoxetine
Bupropion
Guanfacine
Clonidine
By Age Group :
Pediatric and Adolescent
Adult
By Distribution Channel :
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-commerce
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type:
Stimulants
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-stimulants
Atomoxetine
Bupropion
Guanfacine
Clonidine
By Age Group :
Pediatric and Adolescent
Adult
By Distribution Channel :
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-commerce
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type:
Stimulants
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-stimulants
Atomoxetine
Bupropion
Guanfacine
Clonidine
By Age Group :
Pediatric and Adolescent
Adult
By Distribution Channel :
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-commerce
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type:
Stimulants
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-stimulants
Atomoxetine
Bupropion
Guanfacine
Clonidine
By Age Group :
Pediatric and Adolescent
Adult
By Distribution Channel :
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-commerce
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Drug Type:
Stimulants
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-stimulants
Atomoxetine
Bupropion
Guanfacine
Clonidine
By Age Group :
Pediatric and Adolescent
Adult
By Distribution Channel :
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-commerce
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Amneal Pharmaceuticals, Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Eli Lilly And Company
Janssen Pharmaceuticals, Inc.
Noven Pharmaceuticals, Inc.
RespireRx Pharmaceuticals Inc.
Otsuka Pharmaceutical Co., Ltd
Neos Therapeutics, Inc.
American Brivision (Holding) Corporation
Novartis International AG
Takeda Pharmaceutical Company Limited
GlaxoSmithKline plc
Purdue Pharma L.P.
“*” marked represents similar segmentation in other categories in the respective section.